Predictive value of delta-radiomic features for the prognosis of patients with stage IA lung adenocarcinoma.

Feiyang Zhong¹, Wenping Li², Qiaohui Lu², Lijun Wu³, Yuan Fang⁴, Pengxin Yu⁵, Shaohong Zhao⁶

¹Nankai University, Tianjin, China; Department of Radiology, the First Medical Center of the Chinese PLA General Hospital, Beijing, China.

²Department of Radiology, the Sixth Medical Center of the Chinese PLA General Hospital, Beijing, China.

³Department of Radiology, the First Medical Center of the Chinese PLA General Hospital, Beijing, China.

⁴Department of Radiology, Air Force Medical Center, Air Force Medical University, PLA, Beijing, China.

⁵Institute of Advanced Research, Infervision Medical Technology Co., Ltd, Beijing, China.

⁶Nankai University, Tianjin, China; Department of Radiology, the First Medical Center of the Chinese PLA General Hospital, Beijing, China. Electronic address: zhaoshaohong@aliyun.com.

PubMed DOI

Abstract

OBJECTIVES: To evaluate the predictive value of delta-radiomic features for recurrence-free survival (RFS) in patients with stage IA lung adenocarcinoma (LUAD) and to develop an integrated nomogram for risk stratification. MATERIALS AND METHODS: This retrospective study enrolled 647 patients with stage IA LUAD who underwent baseline and follow-up CT scans. Patients were randomly allocated to trai…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.